DiscoverNew Retina Radio by EyetubeASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings
ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

Update: 2024-08-08
Share

Description

Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of continuous dosing of pegcetacoplan (Syfovre, Apellis Pharmaceuticals). What did microperimetry findings reveal about long-term dosing with C3 inhibition? Join us in this episode to find out. 

Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

Retina Today

We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and our services, you agree to our use of cookies as described in our Cookie Policy.